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Outcome and risk factors of ischemic heart disease in chronic uremia.
To determine the prognosis and risk factors for ischemic heart disease in
chronic uremia, a cohort of 432 dialysis patients were followed prospec-
tively from start of dialysis therapy until death or renal transplantation.
Baseline demographic, clinical and echocardiographic data were obtained.
After the initiation of dialysis laboratoxy data were collected at monthly
intervals, and clinical and echocardiographic data at yearly intervals.
Twenty-two percent of patients (N = 95) had either a history of angina
pectoris or myocardial infarction on starting dialysis therapy. Median time
to onset of heart failure was 24 months in those with ischemic heart
disease on initiation of dialysis, compared to 55 months in those without
(P < 0.0001). This effect was independent of age, diabetes and underlying
cardiomyopathy. Median survival was 44 months in those with ischemic
disease compared to 56 months in those without (P = 0.0001). This
adverse impact was independent of age and diabetes mellitus but, when
cardiac failure was added to the Cox's model, ischemic heart disease was
no longer an independent predictor of survival. De novo ischemic heart
disease, not evident on starting dialysis therapy, occurred in 41 (9%)
patients. When compared to patients who never developed ischemic
disease (N = 296; 69%), significant and independent predictors of de novo
disease were older age (P = 0.0007), diabetes mellitus (P = 0.0001), high
blood pressure during follow up on dialysis (P = 0.02) and hypoalbumin-
emia (P = 0.03), whereas anemia was not an independent predictor. LV
mass index was 174 7 g/m2 in those who developed de novo ischemic
disease compared to 155 3 g/m2 (P < 0.001) in those who did not.
Concentric LV hypertrophy, LV dilation and systolic dysfunction were
independent risk factors for de novo ischemic heart disease. We conclude
that ischemic heart disease occurs frequently in dialysis patients, that its
adverse impact is mediated through the development of heart failure, and
that the most important, potentially reversible risk factors are hyperten-
sion, hypoalbuminemia, and underlying cardiomyopathy.
Cardiac disease is the most frequent cause of death in dialysis
patients, a group of patients with a substantially increased mor-
tality rate when compared to the general population [1]. Clinical
manifestations of cardiac disease such as angina, myocardial
infarction and heart failure occur frequently [21. This high burden
of disease results from cardiomyopathy and/or ischemic heart
disease. The former is manifest as concentric LV hypertrophy, LV
dilation or systolic dysfunction [3], and the latter may result from
coronary artery disease or nonatheroscierotic disease. Cardiomy-
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opathy, whether it be manifest as concentric hypertrophy, dilation
or diminished contractility, is an independent predictor of the
development of heart failure and of decreased survival [3—5].
In chronic uremia ischemic heart disease results from nonath-
erosclerotic disease in 27% of cases [6], and silent coronary artery
disease may occur [6, 7]. Unfortunately, noninvasive tests of
coronary perfusion have poor sensitivity and specificity for coro-
nary artery disease [8]. Consequently the diagnosis of coronary
artery disease depends on cardiac catheterization. In longitudinal
epidemiological studies cardiac catheterization of all patients is
impossible. Therefore a clinically defined entity, ischemic heart
disease, becomes by necessity the only feasible event that can be
studied when the condition of interest is inadequate coronary
vessel perfusion. This was the case for the Framingham study [9].
To determine the outcome of, and risk factors for ischemic
heart disease in chronic uremia, a cohort of 432 consecutive
maintenance dialysis patients who survived at least six months
after the initiation of dialysis and who had an echocardiogram at
baseline were included in a longitudinal study. Blood pressure and
laboratory data were collected monthly, and clinical histories and
echocardiograms were obtained yearly. The impact of ischemic
heart disease on cardiomyopathy, heart failure and mortality was
assessed.
To identif' potentially reversible risk factors for ischemia
present during chronic uremia, the effects of hypertension, ane-
mia, hypoabluminemia, and underlying cardiomyopathy on the
development of de novo ischemic heart disease were studied in the
group without ischemic disease on starting dialysis. Our hypoth-
esis was that in addition to risk factors identified in studies of the
general population (age, diabetes, hypercholesterolemia, smoking
and hypertension) [9], LV hypertrophy associated with the under-
lying cardiomyopathy and anemia would predispose these patients
to the development of ischemic heart disease [10].
Methods
Patients
This prospective cohort study was started in the Royal Victoria
Hospital, Montreal, Quebec in 1982, in the Health Sciences
Centre, St. John's, Newfoundland in 1984, and in the Grace
Hospital, St. John's, Newfoundland in 1985. Patients were eligible
for entry to the study if (a) they survived for six months and (b) if
they had a technically satisfactory echocardiogram within a year of
1428
Parfrey et al: Ischemic heart disease 1429
starting renal replacement therapy. Patient recruitment finished
in June 1991. The mean patient follow up was 41 months. Several
reports derived from this longitudinal study have been published
[3—5, 11, 12].
Of 518 consecutive patients who survived at least six months
from the start of ESRD therapy, a cohort of 433 (84% of those
eligible) entered the study. One study patient was treated only
with renal transplantation and was excluded from the current
analysis. Eighty-five patients were excluded for the following
reasons: failure to obtain a technically adequate echocardiogram
within one year of starting therapy (71 patients), started therapy
elsewhere (7 patients), charts mislaid (5 patients), refusal to
participate (2 patients).
The mean age of the cohort was 51 17 years, 64% were male,
27% had diabetes mellitus, 29% hypertension for> 10 years, 31%
had heart failure on starting dialysis, and 22% ischemic heart
disease. The cohort was almost entirely Caucasian. The age and
proportion of diabetic patients were similar to other Canadian
end-stage renal disease programs [2]. Compared to a typical
program in the United States there was a higher proportion of
males, lower percentage of diabetics, and much higher proportion
of Caucasians [1]. A total of 61% were treated predominantly with
hemodialysis and 39% with peritoneal dialysis.
Data collection
At baseline and at yearly intervals thereafter, a clinical assess-
ment was undertaken to detect the presence of cardiovascular
disease. At monthly intervals the data collected included blood
pressure, hemoglobin, serum creatinine, calcium, phosphorus,
alkaline phosphatase and albumin levels. Blood pressure and
blood tests were carried out immediately prior to dialysis in
hemodialysis patients. Blood pressure was measured in the con-
tralateral arm in patients with patent arteriovenous fistulae or
grafts. For each subject blood pressure and laboratory variables
were reported as the mean of the monthly values while on dialysis
therapy. At yearly intervals all changes related to renal replace-
ment therapy, blood transfusions, use of recombinant human
erythropoietin, antihypertensive and cardiac medication use, ad-
missions to hospital, and autopsy notes were recorded.
Baseline and annual echocardiography were performed using
M-mode and two-dimensional ultrasonography. Left ventricular
mass index was calculated according to the Penn convention [13].
Left ventricular cavity volume was calculated by the formula of
Pombo, Troy and Russell [14]. The initial echocardiogram was
performed 3 4 (mean SD) months following the start of
ESRD therapy. A total of 298 patients remained alive or untrans-
planted in the study at one year, and 275 patients had a repeat
echocardiogram, at an interval of 16 10 months following the
start of dialysis therapy. This patient subset was almost identical to
the parent group of 432 patients, with no statistically significant
differences in terms of baseline clinical and echocardiographic
parameters [3].
Definitions
The following definitions were used. Myocardial infarction was
defined as a diagnosis of myocardial infarction made by the
attending physician, confirmed by review of history, electrocardio-
grams and cardiac enzymes. Angina pectoris consisted of precor-
dial chest pain, precipitated by exertion or stress, relieved by rest
or nitrate therapy. Ischemic heart disease was myocardial infarc-
tion or angina pectoris. Heart failure was defined as dyspnea plus
two of the following: raised jugular venous pressure, bibasalar
crackles, pulmonary venous hypertension or interstitial edema on
chest x-ray [111. De novo ischemic heart disease was admission for
ischemic heart disease while on dialysis therapy in a patient
without a history of ischemic heart disease at baseline. Echocar-
diographic systolic dysfunction was defined as fractional shorten-
ing  25%. LV dilation was the LV cavity volume > 90 mI/rn2
[14], and no systolic dysfunction. LV hypertrophy was LV mass
index> 131 g/m2 in males, > 100 gJm2 in females [15]. Concentric
LV hypertrophy was LV hypertrophy with normal cavity volume
[16], and no systolic dysfunction. "Normal" LV was defined as the
absence of hypertrophy, dilation and systolic dysfunction. It is
possible that such a LV could have diastolic dysfunction. Predom-
inant mode of dialysis therapy was when > 50% of the total
dialysis time was on a particular mode of dialysis (peritoneal
dialysis or hemodialysis).
Analysis
For clinical events, hemoglobin, blood pressure and biochem-
istry results were averaged from the monthly values, from the
beginning of dialysis therapy up to the development of the event
in question. For each outcome reported here, the impact of
ischemic heart disease was adjusted for age, diabetes mellitus,
anemia, serum albumin, and blood pressure. For the analyses of
time to development of ischemic heart disease, and time to death,
patients were censored at the time of renal transplantation or at
final follow up. Normally distributed continuous variables were
compared using t-tests or analysis of variance. Categorical vari-
ables were compared using chi-squared analysis. The independent
impact of ischemic heart disease on death rates, and the factors
associated with de novo development of ischemic heart disease
were assessed using Cox's proportional hazards modelling. All
statistical tests are two-tailed with a P-value less than 0.05 taken to
indicate statistical significance. All multivariate analyses incorpo-
rated a stepping procedure, and were performed using BMDP
software [171.
Results
Ischemic heart disease on initiation of dialysis
In this cohort, 22% (N = 95) had ischemic heart disease on
starting dialysis, 56% (N = 53) of whom had a myocardial infarct,
82% (N = 78) angina, 15% (N = 14) coronary artery bypass
grafting and 1% (N = 1) coronary angioplasty.
Table 1 shows the clinical, biochemical and echocardiographic
characteristics of the groups with and without ischemic heart
disease on starting dialysis. The group with ischemic disease were
significantly older (61 vs. 48 years, P < 0.00 1), with lower diastolic
blood pressure, higher hemoglobin, and lower serum creatinine. It
is likely that the higher baseline hemoglobin level and lower
serum creatinine reflect earlier prescription of dialysis in the
ischemic group. A higher proportion had diabetes mellitus and
also hypertension for > 10 years. Sixty percent also had heart
failure compared to 23% of those without ischemic heart disease
(P = 0.001). On echocardiography those with ischemic disease
had a higher left atrial diameter, higher LV end systolic diameter,
lower fractional shortening, and a higher proportion with systolic
dysfunction.
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Age years
Systolic blood pressure
mm Hg
Diastolic blood
pressure mm Hg
Serum cholesterol
mmol/liter
Hemoglobin giliter
Serum creatinine
p.mol/liter
Serum calcium mmol/
liter
Serum phosphorus
mmol/liter
Serum albumin g/liter
Left atrial diameter
mm
LV end diastolic
diameter mm
LV end systolic
diameter mm
LV posterior wall
thickness in diastole
N % N %
Male 67 71 212 63
Diabetes mellitus 37 39 79 23
Hypertension > 10 years 39 41 87 26
Current smoker 36 38 115 34
Heart failure 56 60 77 23
Concentric LV hypertrophy 35 40 134 41
LV dilation 21 24 97 30
Systolic dysfunction 30 26 38 12
Global dyskinesia 12 13 26 8
Segmental dyskinesia 23 25 19 6
STIT wave changes on ECG 74 81 130 39
Data are means SD.
A multiple logistic regression model (Table 2) was performed
which included age, gender, diabetes, serum cholesterol, hyper-
tension for > 10 years and smoking. This revealed that older age,
male gender and probably diabetes mellitus were important
associations of the presence of ischemic disease on starting
dialysis therapy.
Impact of ischemic heart disease on heart failure
Ischemic heart disease was significantly associated with the
presence of heart failure on starting dialysis therapy (odds ratio
1.98, P = 0.02) independent of age, diabetes mellitus, systolic
dysfunction, LV hypertrophy, baseline hemoglobin, blood pres-
sure and serum albumin.
Figure 1 shows the time to onset of heart failure following the
initiation of dialysis in patients with and without ischemic heart
Table 2. Predictors of the presence of ischemic heart disease in 419a
patients starting dialysis therapy, using multiple logistic regression
Odds ratio P
Older age (per year) 1.06 <0.0001
Male gender 1.9 0.007
Diabetes mellitus 2.2 0.06
Hypertension > 10 years 1.6 0.09
Serum cholesterol NS NS
Smoking NS NS
disease. The median time to heart failure was 24 months in the
former group and 55 months in the latter (P < 0.0001). The risk
of developing heart failure following the start of dialysis therapy in
patients with ischemic disease at baseline, was independent of age,
diabetes mellitus, and underlying cardiomyopathy (relative risk =
3.0, P < 0.001).
Mortality
Figure 2 shows the actual mortality in patients with and without
ischemic heart disease at baseline. Median survival was 44 months
in the former and 56 months in the latter. The relative risk of
death was 1.48 (standard error = 0.17, P = 0.03) independent of
age and diabetes mellitus (Table 3). When heart failure on
starting dialysis was included in the model, ischemic heart disease
was no longer an independent predictor of death (Table 3).
Risk factors for de novo development of ischemic heart disease
Three hundred and thirty-six patients did not have ischemic
heart disease on starting dialysis, 41(12%) of whom subsequently
developed ischemic heart disease. This was manifest as angina in
30 patients and myocardial infarction in 11 patients. The group
who subsequently developed de novo ischemic heart disease, when
compared to those who did not, were significantly older (59 vs. 47
years, P < 0.001), a significantly higher proportion were diabetic,
had hypertension for> 10 years, already had systolic dysfunction
or LV dyskinesia at baseline, and LV mass index was significantly
Table 1. Clinical, biochemical and echocardiographic characteristics of
end-stage renal disease patients with (N = 95) and without ischemic
heart disease (N = 337) on initiation of dialysis
No ischemic
heart disease
48 I
152 1
84 1
P
<0.001
NS
0.03
5.21 0.08 NS 13 patients had incomplete data sets
82 1
918 23
Ischemic
heart disease
61 I
149 2
80 1
5.52 0.2
90 2
791 31
2.11 0.03
2.14 0.08
34.7 0.5
40.8 0.8
52.8 0.8
36.4 0.9
12.3 0.2
31.2 1.0
165 488 4
<0.001
0.001
NS
NS
NS
0.001
NS
0.9
0.8
0.7
0.6
0.5
2.08 0.02
2.19 0.05
34.3 0.3
37.9 0.3
51.5 0.4
33.7 0.4
12.1 0.1
34.7 0.4
157 384 2
mm
Fractional shortening
%
LV mass index g/m2
LV volume
No ischemic heart disease
0.005 0.4
0.3
NS 0.2
0.1
0
0 6 12 18 24 30 36 42 48 54 60
0.001
NS
NS
P
NS
0.002
0.004
NS
<0.001
NS
NSa
<o.oor'
NS
<0.001
<0.001
Time, months
Fig. 1. Time to onset of heart failure following the start of dialysis therapy in
patients with and without ischemic heart disease.
a Reference group: normal echocardiogram
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0.9
0.8
0.7
0.6
>
0.5
Cl) 0.4
0.3
0.2
0.1
0
Fig. 2. Mortality in dialysis patients with and without ischemic heart disease
at the start of dialysis therapy.
Table 3. The effect of age, diabetes, ischemic heart disease and heart
failure on survival using Cox's proportional hazards model
Odds ratio P
Model A
Age per year 1.03 <0.001
Diabetes mellitus 2.24 <0.001
Ischemic heart disease 1.48 <0.001
Model B
Age per year 1.03 <0.001
Diabetes 2.00 <0.001
Heart failure 1.93 <0.001
Ischemic heart disease — NS
In Model A heart failure was not included as a potential predictor of
death and in Model B it was included.
higher (Table 4). During dialysis therapy the group who devel-
oped de novo ischemic disease had higher systolic blood pressure
(152 vs. 144 mm Hg, P = 0.03) and lower serum albumin.
Table 5 shows that age, diabetes, echocardiographic diagnosis
at baseline, hypertension and hypoalbuminemia during dialysis
therapy were independent and significant predictors of the devel-
opment of de novo ischemic disease, whereas anemia was not.
Discussion
Ischemic heart disease is frequently present in patients starting
end-stage disease therapy, and these patients have a shorter
survival than those without heart disease. This adverse prognosis
is mediated via heart failure, as shown by the observation that
ischemic heart disease is not a significant predictor of survival
when age, diabetes mellitus, and heart failure are taken into
account. These findings may partly reflect the six month survival
needed as a study entry criterion, particularly as one of the
Centres involved in the study has reported that ischemic heart
disease is an important predictor of mortality independent of
cardiac failure, within the first six months of chronic dialysis
therapy [18].
Heart failure is a clinical diagnosis. Excess salt and water
retention may be an exacerbating cause of heart failure in chronic
uremia, but it is our opinion that the development of heart failure
usually reflects cardiac abnormalities. On starting dialysis therapy
Table 4. Characteristics of ESRD patients without ischemic heart
disease on starting dialysis therapy comparing those who developed de
novo ischemic heart disease following the initiation of dialysis (N = 41)
and those who did not (N = 295)
De novo
ischemic
disease
No
ischemic
disease P
Age years 59 2 47 1 0.001
Serum cholesterol 5.55 0.3 5.17 0.09 NS
mmol/liter
Systolic blood pressure 152 3 144 1 0.03
mm Hg
Diastolic blood pressure 82 2 82 1 NS
mm Hg
Mean hemoglobin 87 3 87 1 NS
during dialysis giliter
Mean serum calcium 2.27 0.04 2.32 0.Ol NS
during dialysis
mmol/liter
Mean serum 1.91 0.1 1.92 0.03 NS
phosphorus during
dialysis mmol/liter
Mean serum alkaline 155 33 107 6 NS
phosphatase during
dialysis piliter
Mean serum albumin 34.5 0.9 37.3 0.3 0.005
during dialysis g/liter
Left atrial diameter mm 38.9 1.0 37.7 0.4 NS
LV end diastolic 52.1 1.1 51.3 0.4 NS
diameter mm
LV end systolic 34.6 1.3 33.5 0.4 NS
diameter mm
LV posterior wall 12.8 0.3 12.1 0.2 0.03
thickness in diastole
mm
Fractional shortening % 33.3 1.4
LV mass index g/m2 174 7
LV volume ml/m2 87 7
34.9 0.4
155 3
83± 2
N %
NS
0.02
NS
N %
Male 25 61 186 63 NS
Diabetes mellitus 20 49 58 20 <0.001
Hypertension > 10 years 23 56 62 21 <0.001
Heart failure on starting dialysis 16 39 61 21 0.02
Current smoker 16 39 98 33 NS
Concentric LV hypertrophy 20 53 114 39 0.006
LV dilation 9 24 88 30 0.06U
Systolic dysfunction 8 21 30 10 0.001U
Global dyskinesia 7 17 18 6 0.02
Segmental dyskinesia 4 10 14 5 NS
ST/T wave changes on ECG 28 68 101 35 <0.001
Clinical and echocardiographic characteristics on initiation of dialysis,
together with mean of serial blood pressure and biochemistry levels after
starting dialysis are presented.
U Reference group: normal echocardiogram
33% of patients with heart failure have systolic dysfunction (vs.
7% in those without heart failure, P < 0.0001), 36% have LV
dyskinesia (vs. 11% in those without, P < 0.0001), only 11% have
a normal echocardiogram (vs. 26% in those without, P 0.0009),
LV mass index is higher (172 vs. 152 g/m2, P < 0.0001), and
fractional shortening is lower (30.5 vs. 35.4%, P < 0.0001) [111.
Furthermore, excess weight gains between dialyses are not asso-
ciated with the development of de novo heart failure [11]. Finally,
patients who presented with heart failure have a substantially
worse prognosis than those who do not [11],
Heart failure reflects either systolic or diastolic dysfunction. A
0 6 12 18 24 30 36 42 48 54 60
Time, months
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Table 5. Independent predictors of the development of de novo
ischemic heart disease during dialysis therapy, using Cox's
regression model
Adjusteda
Relative Risk P
Predictors present on starting dialysis
Age years 1.05 <0.001
Diabetes mellitus 3.97 <0.001
Serum cholesterol mmol/liter NS NS
Current smoker NS NS
Echocardiographic diagnosis
-Normal (reference group) — —
-Concentric LV hypertrophy 5.92 0.01
-LV dilation 5.35 0.02
-Systolic dysfunction 12.2 0.002
Predictors measured during life on
dialysis
Hemoglobin g/liter NS NS
Diastolic blood pressure mm Hg 1.04 0.03
Serum albumin g/liter 0.93 0.03
Patients without ischemic heart disease on starting dialysis were ana-
lyzed and the outcome event studied was the development of de novo
ischemic heart disease. Blood pressure and laboratory measurements were
averaged from the start of dialysis until the development of ischemic heart
disease.
a Adjusted for baseline age, diabetes, serum cholesterol, smoking and
serial blood pressure while on dialysis therapy
bNS, non-significant
third of the patients with heart failure upon starting dialysis
therapy had systolic dysfunction [11], implying that diastolic
dysfunction is also an important cause of heart failure. We did not
measure diastolic function, hut diastolic abnormalities, character-
ized by a significant lowering of the E/A ratio of the transmitral
velocity, occur in hemodialysis patients [19]. The importance of
the underlying cardiomyopathy on the development of heart
failure is shown by the observations that patients with concentric
LV hypertrophy, LV dilation or systolic dysfunction all had a
substantially increased risk of developing heart failure after the
initiation of dialysis, independent of age, diabetes and ischemic
heart disease [3]. However, ischemic heart disease is an additional
independent and significant predictor of the development of heart
failure during life on dialysis.
In chronic uremia LV pressure overload results in concentric
LV hypertrophy, and LV volume overload results in LV dilation
and compensatory eccentric LV hypertrophy. The etiology of both
types of LV hypertrophy is multifactorial [3]. It is likely that the
occurrence of myocyte death in the presence of concentric or
eccentric hypertrophy would be catastrophic [20]. Ischemia pre-
disposes to cell death, and consequently could lead to LV dilation
and eventually to systolic dysfunction. In the current study isch-
ernie heart disease was associated with the presence of systolic
dysfunction both at baseline and on follow-up a year later [3]. It
was also associated with LV dilation in patients with normal
systolic function on follow-up echocardiogram [3]. However, the
impact of ischemic heart disease on the development of heart
failure was exerted not only through the development of cardio-
myopathy, but also probably through other mechanisms because
the risk of developing heart failure in patients with ischemic
disease was independent of age, diabetes, and underlying cardio-
myopathy.
In longitudinal studies of risk factors for disease the best group
to study is the group without the disease of interest at baseline, in
whom risk factor data can be prospectively collected prior to the
development of disease. The importance of potential risk factors
can then be compared in those who subsequently develop the
disease and in those who don't. In the current study patients
without ischemic heart disease on starting dialysis comprised the
cohort of interest and the clinical outcome of interest was the
subsequent development of de novo ischemic heart disease.
However, at baseline there were substantial differences between
those who developed de novo ischemic heart disease and those
who did not. The former group were older, a significantly higher
proportion had diabetes mellitus, hypertension for > 10 years,
systolic dysfunction at baseline, dyskinesia on echocardiogram,
and the LV mass index was significantly higher. Therefore, it is
likely that the pathogenic mechanisms predisposing to ischemia
were already activated prior to the initiation of dialysis therapy.
Ischemic symptoms result form a reduction in coronary vaso-
dilator reserve and altered myocardial oxygen delivery and use.
The presence of LV hypertrophy and anemia may predispose to
ischemia, the former by reducing coronary reserve and the latter
by decreasing oxygen delivery. As the demand for oxygen in-
creases the coronary vasculature dilates above basal, and a further
increase in myocardial oxygen requirement may not be met with
an adequate increase in coronary flow, especially if there are
pathologic changes in the large or small coronary vessels [8, 10]. In
the current study LV mass index was significantly higher in those
who subsequently developed de novo ischemic disease. Further-
more, the underlying manifestation of cardiomyopathy, whether it
was concentric LV hypertrophy, LV dilation or systolic dysfunc-
tion, was an independent risk factor for the subsequent develop-
ment of de novo ischemic heart failure. However, there was no
evidence that anemia predisposed to de novo ischemic heart
disease.
Hypertension was one risk factor for ischemic heart disease,
amenable to intervention, which was identified during follow-up
on dialysis. Mean systolic blood pressure was 152 mm Hg on
average during follow-up in those who developed de novo isch-
emic disease, compared to 144 mm Hg in those who did not.
Hypertension may exert its pathogenic effect through the devel-
opment of coronary artery disease [91, or through the develop-
ment of LV hypertrophy [21], which in turn may be associated
with small vessel smooth muscle hypertrophy and endothelial
abnormalities [22], which can diminish the coronary reserve.
In addition to hypertension the other risk factor identified was
hypoalbuminemia. It is unclear how hypoalbuminemia could
predispose to the subsequent development of ischemic heart
disease. Perhaps this could occur through its association with a
hypercoagulable state: low serum albumin levels were the best
predictor of vascular access thrombosis in the Canadian Hemo-
dialysis Morbidity Study [2]. It is also possible that hypoalbumin-
emia marks for nutritional deficiencies which predispose to hy-
perhomocysteinemia [23]. Hyperhomocysteinemia is a risk factor
for atherothrombotic cardiovascular disease in both the general
[24] and ESRD populations [25]. It is also possible that hypoalbu-
minemia is associated with hyperlipidemia. However, the adverse
impact of hypoalbuminemia was independent of serum choles-
terol level.
The current study measured only serum cholesterol levels
during follow up. It is possible that its adverse impact was
confounded by low serum cholesterol levels caused by diminished
intake. Furthermore, it is likely that other abnormalities in the
lipoprotein profile and in lipoprotein compositional abnormalities
have pathogenic importance. Dialysis patients have a severe
defect in postprandial lipoprotein metabolism, which exposes the
vascular wall to high chylomicron remnant concentrations 1261.
Hemodialysis patients have elevated intermediate density lipopro-
tein levels, heterogeneity in the distribution of LDL and apopro-
tein specific HDL subpopulations, abnormalities in the size and
composition of both LDL and HDL [27]. In addition, LDL from
uremic patients appears to be more susceptible to in vitro and in
vivo oxidation compared to control subjects [28]. Modification of
the recognition of LDL by cells may occur in hemodialysis
patients [29]. In hemodialysis patients with or without diabetes
rnellitus serum lipoprotein(a) levels are higher than in normal
controls [30, 31].
In one prospective study of diabetic patients on hemodialysis,
patients subsequently dying form myocardial infarction had sig-
nificantly higher median cholesterol than survivors, and higher
LDL cholesterol, LDL/HDL ratio and apolipoprotein B [32]. In a
second prospective study of 91 chronic dialysis patients high levels
of LDL cholesterol were associated with coronary and cerebro-
vascular events [331. In a third study lipoprotein(a) was a risk
factor for subsequent ischemic events [34]. The prognostic impact
of lipoprotein remnants, oxidized LDL, or altered lipoproteins,
has not been reported in chronic uremia.
The length density and the surface density of capillaries in the
heart of uremic rats are significantly more reduced than in rats
with Goldblatt hypertension, matched for left ventricular weight
and for blood pressure level [35]. In the current study we did not
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measure the quantity of dialysis delivered and thus were unable to
determine whether the degree of uremia was associated with the
development of ischemic disease. Once other risk factors were
taken into account we were unable to demonstrate an impact of
modality of therapy, that is, having included blood pressure,
hemoglobin, serum albumin and cholesterol in the multivariate
model no extra risk was identified whether patients were treated
predominantly with hemo- or peritoneal dialysis.
Susceptibility to myocardial ischemia may further increase as a
result of dysregulation of high energy phosphate compounds
during ischemia. A reduced phosphocreatine-ATP ratio under
hypoxic stress has been observed in the myocardium of uremic
animals [361. Hyperparathyroidism plays a critical role in the
genesis of impaired energy production, transfer and utilization by
the myocardium [37], and thus could increase susceptibility to
ischemia. There is evidence that hypocalcemia, perhaps through
concomitant hyperparathyroidism, may be associated with the
development of ischemic disease [38].
Figure 3 outlines the conclusions from the discussion. Older
age, diabetes mellitus, hypertension, hypoalbuminemia through
unknown mechanisms, and the underlying cardiomyopathy are
risk factors for the development of ischemic heart disease. Other
risk factors include dyslipidemia and hyperhomocysteinemia.
Pathogenic mechanisms predisposing to ischemia are already
activated prior to the initiation of dialysis therapy. While on
dialysis potentially reversible risk factors include hypertension,
hypoalbuminemia, dyslipidemia and LV hypertrophy. Ischemic
disease is associated with LV dilation, systolic dysfunction and
heart failure. The adverse impact of ischemic disease is mediated
via heart failure, which is a strong predictor of earlier death.
Reprint requests to Dr. Patrick Parfrey, Division of Nephrology, Health
Sciences Centre, 300 Prince Philip Drive, St. John's, Newfoundland, A1B 3V6
Canada.
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